image
Healthcare - Drug Manufacturers - General - NASDAQ - FR
$ 52.27
-2.64 %
$ 129 B
Market Cap
22.05
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one SNY stock under the worst case scenario is HIDDEN Compared to the current market price of 52.3 USD, Sanofi is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one SNY stock under the base case scenario is HIDDEN Compared to the current market price of 52.3 USD, Sanofi is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one SNY stock under the best case scenario is HIDDEN Compared to the current market price of 52.3 USD, Sanofi is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SNY

image
$60.0$60.0$58.0$58.0$56.0$56.0$54.0$54.0$52.0$52.0$50.0$50.0$48.0$48.0$46.0$46.0$44.0$44.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
44.3 B REVENUE
-3.80%
7.25 B OPERATING INCOME
-7.91%
5.5 B NET INCOME
1.78%
9.08 B OPERATING CASH FLOW
-11.47%
-4.41 B INVESTING CASH FLOW
28.92%
-5.76 B FINANCING CASH FLOW
28.43%
10.6 B REVENUE
38.99%
2.28 B OPERATING INCOME
298.78%
1.87 B NET INCOME
0.00%
2.09 B OPERATING CASH FLOW
0.00%
-776 M INVESTING CASH FLOW
0.00%
-592 M FINANCING CASH FLOW
0.00%
Balance Sheet Sanofi
image
Current Assets 42.6 B
Cash & Short-Term Investments 7.93 B
Receivables 10.6 B
Other Current Assets 24 B
Non-Current Assets 90.2 B
Long-Term Investments 3.26 B
PP&E 11.6 B
Other Non-Current Assets 75.4 B
5.97 %8.00 %18.10 %8.74 %56.74 %Total Assets$132.8b
Current Liabilities 29.2 B
Accounts Payable 7.55 B
Short-Term Debt 4.47 B
Other Current Liabilities 17.1 B
Non-Current Liabilities 25.8 B
Long-Term Debt 13.4 B
Other Non-Current Liabilities 12.3 B
13.74 %8.14 %31.20 %24.46 %22.47 %Total Liabilities$54.9b
EFFICIENCY
Earnings Waterfall Sanofi
image
Revenue 44.3 B
Cost Of Revenue 13.2 B
Gross Profit 31.1 B
Operating Expenses 23.8 B
Operating Income 7.25 B
Other Expenses 1.76 B
Net Income 5.5 B
45b45b40b40b35b35b30b30b25b25b20b20b15b15b10b10b5b5b0044b(13b)31b(24b)7b(2b)5bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
70.18% GROSS MARGIN
70.18%
16.38% OPERATING MARGIN
16.38%
12.55% NET MARGIN
12.55%
7.17% ROE
7.17%
4.19% ROA
4.19%
5.50% ROIC
5.50%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sanofi
image
9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 5.5 B
Depreciation & Amortization 3.59 B
Capital Expenditures -3.2 B
Stock-Based Compensation 0
Change in Working Capital -615 M
Others 517 M
Free Cash Flow 5.89 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sanofi
image
Wall Street analysts predict an average 1-year price target for SNY of $58.5 , with forecasts ranging from a low of $48.1 to a high of $64 .
SNY Lowest Price Target Wall Street Target
48.1 USD -8.04%
SNY Average Price Target Wall Street Target
58.5 USD 11.94%
SNY Highest Price Target Wall Street Target
64 USD 22.44%
Price
Max Price Target
Min Price Target
Average Price Target
64646262606058585656545452525050484846464444Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
1.61 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
2.500002.500002.000002.000001.500001.500001.000001.000000.500000.500000.000000.000001.6181.621.631.631.5771.581.8611.861.7391.741.7531.751.9061.911.7471.750.2970.301.9031.902.036912.041.609121.612015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Sanofi
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sanofi: Investing in prevention builds Europe's health and competitiveness WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- As the Polish Presidency of the EU Council enters its final stage health policy remains central to Europe's strategic agenda. At the European Economic Congress in Katowice, discussions reflected both the Presidency's efforts to strengthen healthcare resilience and drive digital transformation, and a broader consensus that prevention, innovation, and life science leadership must be at the core of Europe's long-term strategy. Sanofi's experts highlighted the pivotal role of immunization, respiratory health, and sustainable innovation in building a healthier and competitive Europe. globenewswire.com - 2 weeks ago
Press Release: Annual General Meeting of April 30, 2025 Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025 Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders' Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. globenewswire.com - 2 weeks ago
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. globenewswire.com - 2 weeks ago
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race globenewswire.com - 3 weeks ago
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race globenewswire.com - 3 weeks ago
Sanofi (SNY) Q1 2025 Earnings Call Transcript Sanofi (NASDAQ:SNY ) Q4 2024 Earnings Call Transcript Q1 2025 Earnings Conference Call April 25, 2025 7:00 AM ET Company Participants Thomas Kudsk Larsen - Head, Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research & Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Conference Call Participants Richard Vosser - JPMorgan Luisa Hector - Berenberg Colleen Garvey - Guggenheim Ben Jackson - Jefferies Peter Verdult - BNP Exane Jo Walton - UBS Graham Parry - BofA James Quigley - Goldman Sachs Florent Cespedes - Bernstein Sarita Kapila - Morgan Stanley Simon Baker - Redburn Thomas Kudsk Larsen Hello everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. seekingalpha.com - 3 weeks ago
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025. zacks.com - 3 weeks ago
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth. wsj.com - 3 weeks ago
Innate Pharma Announces €15M Investment by Sanofi MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscribed by Sanofi. As announced on April 23, 2025, and given the satisfactory market conditions, Sanofi has agreed to subscribe to 8,345,387 new ordinary shares of Innate, at a price of €1.7974 per share, representing a total capital increase of €14,999,998.59 (€417,269.35 in nominal amount and €14,582,729.24 o. businesswire.com - 3 weeks ago
Sanofi's quarterly profit beats estimates on Dupixent boost, newer products France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines. reuters.com - 3 weeks ago
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO Dupixent sales were €3.5 billion, up 20.3% Vaccines sales were €1.3 billion, up 11.4%, driven by favorable Beyfortus phasing Research and Development expenses reached €1.8 billion, up 6.9% Selling, general and administrative expenses were €2.2 billion, up 3.8% Business EPS was €1.79, up 15.7% at CER and up 17.0% reported; IFRS EPS was €1.52 Pipeline continued to deliver Six regulatory approvals across medicines in immunology, rare diseases, and oncology Recent new data from the mid-stage pipeline unlocks late-stage studies in asthma and skin diseases, broadening and deepening the scope in immunology Sustainability strategy Updated sustainability strategy focuses on access to healthcare, environmental impact, and resilience of healthcare systems. 70% of the portfolio and >75% of the pipeline target diseases that are impacted by climate and environmental challenges Capital allocation The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q23 Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager4 Guidance confirmed In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5. globenewswire.com - 3 weeks ago
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on Wednesday. reuters.com - 3 weeks ago
8. Profile Summary

Sanofi SNY

image
COUNTRY FR
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 129 B
Dividend Yield 0.00%
Description Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Contact 54, Rue La BoEtie, Paris, 75008 https://www.sanofi.com
IPO Date July 1, 2002
Employees 82878
Officers Mr. Paul Hudson Chief Executive Officer & Director Mr. Laurent Gilhodes Principal Accounting Officer and Vice President of Corporate Accounting Mr. Pierre Chancel Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing Mr. Thomas Kudsk Larsen Head of Investor Relations Mr. Roy Papatheodorou Executive Vice President & General Counsel Ms. Madeleine Roach Executive Vice President & Head of Business Operations Dr. Josephine Fubara Chief Science Officer of Consumer Health Care Ms. Natalie Bickford Executive Vice President & Chief People Officer Mr. Dante Beccaria Global Compliance Officer & Vice President Mr. François-Xavier Roger Executive Vice President & Chief Financial Officer